These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 32052853)

  • 1. Safety assessment of excipients (SAFE) for orally inhaled drug products.
    Metz JK; Scharnowske L; Hans F; Schnur S; Knoth K; Zimmer H; Limberger M; Groß H; Lehr CM; Hittinger M
    ALTEX; 2020; 37(2):275-286. PubMed ID: 32052853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pulmonary delivery of scutellarin solution and mucoadhesive particles in rats.
    Liu XB; Ye JX; Quan LH; Liu CY; Deng XL; Yang M; Liao YH
    Eur J Pharm Biopharm; 2008 Nov; 70(3):845-52. PubMed ID: 18675905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Excipient pharmacokinetics and profiling.
    Loftsson T
    Int J Pharm; 2015 Mar; 480(1-2):48-54. PubMed ID: 25596414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Overview of Pharmaceutical Excipients: Safe or Not Safe?
    Abrantes CG; Duarte D; Reis CP
    J Pharm Sci; 2016 Jul; 105(7):2019-26. PubMed ID: 27262205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and regulatory review of dyes commonly used as excipients in pharmaceutical and nutraceutical applications.
    Pérez-Ibarbia L; Majdanski T; Schubert S; Windhab N; Schubert US
    Eur J Pharm Sci; 2016 Oct; 93():264-73. PubMed ID: 27531552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Importance of Propellants and Excipients in Pharmaceutical Topical Aerosol.
    Patra M; Bhattacharya S; Patnaik M
    Curr Drug Deliv; 2017; 14(8):1106-1113. PubMed ID: 28290242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biopharmaceutical evaluation of surface active ophthalmic excipients using in vitro and ex vivo corneal models.
    Juretić M; Cetina-Čižmek B; Filipović-Grčić J; Hafner A; Lovrić J; Pepić I
    Eur J Pharm Sci; 2018 Jul; 120():133-141. PubMed ID: 29702232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Formulation strategy and use of excipients in pulmonary drug delivery.
    Pilcer G; Amighi K
    Int J Pharm; 2010 Jun; 392(1-2):1-19. PubMed ID: 20223286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicity of excipients--a Food and Drug Administration perspective.
    Osterberg RE; See NA
    Int J Toxicol; 2003; 22(5):377-80. PubMed ID: 14555410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytotoxicity screening of emulsifiers for pulmonary application of lipid nanoparticles.
    Steiner V; Öhlinger K; Corzo C; Salar-Behzadi S; Fröhlich E
    Eur J Pharm Sci; 2019 Aug; 136():104968. PubMed ID: 31233864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery.
    Sakagami M
    Adv Drug Deliv Rev; 2006 Oct; 58(9-10):1030-60. PubMed ID: 17010473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Semifluorinated alkanes--a new class of excipients suitable for pulmonary drug delivery.
    Tsagogiorgas C; Krebs J; Pukelsheim M; Beck G; Yard B; Theisinger B; Quintel M; Luecke T
    Eur J Pharm Biopharm; 2010 Sep; 76(1):75-82. PubMed ID: 20685332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulmonary formulations: what remains to be done?
    Weers JG; Bell J; Chan HK; Cipolla D; Dunbar C; Hickey AJ; Smith IJ
    J Aerosol Med Pulm Drug Deliv; 2010 Dec; 23 Suppl 2():S5-23. PubMed ID: 21133800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro toxicity screening of polyglycerol esters of fatty acids as excipients for pulmonary formulations.
    Fröhlich E; Öhlinger K; Meindl C; Corzo C; Lochmann D; Reyer S; Salar-Behzadi S
    Toxicol Appl Pharmacol; 2020 Jan; 386():114833. PubMed ID: 31756429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The STEP (Safety and Toxicity of Excipients for Paediatrics) database: part 2 - the pilot version.
    Salunke S; Brandys B; Giacoia G; Tuleu C
    Int J Pharm; 2013 Nov; 457(1):310-22. PubMed ID: 24070789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A perspective on testing of existing pharmaceutical excipients for genotoxic impurities.
    Brusick DJ
    Regul Toxicol Pharmacol; 2009 Nov; 55(2):200-4. PubMed ID: 19607870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A European perspective on orally inhaled products: in vitro requirements for a biowaiver.
    García-Arieta A
    J Aerosol Med Pulm Drug Deliv; 2014 Dec; 27(6):419-29. PubMed ID: 25238116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhalation aspects of therapeutic aerosols.
    Leach CL
    Toxicol Pathol; 2007 Jan; 35(1):23-6. PubMed ID: 17325969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The MTT assay as tool to evaluate and compare excipient toxicity in vitro on respiratory epithelial cells.
    Scherliess R
    Int J Pharm; 2011 Jun; 411(1-2):98-105. PubMed ID: 21453764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Raman characterization and chemical imaging of biocolloidal self-assemblies, drug delivery systems, and pulmonary inhalation aerosols: a review.
    Mansour HM; Hickey AJ
    AAPS PharmSciTech; 2007 Nov; 8(4):E99. PubMed ID: 18181559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.